* BioDiem confirms successful and abundant growth of its virus in VIVALIS' proprietary EB66(®) cell line in Stage 1 of its collaboration with VIVALIS. * The next stage of the project will use known ...
LONDON (Reuters) - France's Vivalis is set to buy Intercell in a deal valuing the Austrian vaccine maker at around 133 million euros ($174 million), and creating an enlarged player in the European ...
Companies will collaborate on antibody discovery against multiple targets. Vaccines company Sanofi Pasteur is paying Vivalis €3 million up front for exclusive access to the latter’s Humalex® platform ...
Firm is developing VLP-based vaccines. Vivalis has granted Novavax the right to use its EB66® cell line for the production of VLP-based vaccines against several new potential viruses. The EB66 cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results